Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human blood expression for Huntington's disease versus control

ABSTRACT: Affymetrix U133A expression levels for 12 symptomatic and 5 presymptomatic Huntington's disease patients versus 14 healthy controls. Keywords: other

ORGANISM(S): Homo sapiens

SUBMITTER: Dimitri Krainc

PROVIDER: E-GEOD-1751 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.

Borovecki F F Lovrecic L L Zhou J J Jeong H H Then F F Rosas H D HD Hersch S M SM Hogarth P P Bouzou B B Jensen R V RV Krainc D D

Proceedings of the National Academy of Sciences of the United States of America 20050725 31

Huntington's disease (HD) is an autosomal dominant disorder caused by an expansion of glutamine repeats in ubiquitously distributed huntingtin protein. Recent studies have shown that mutant huntingtin interferes with the function of widely expressed transcription factors, suggesting that gene expression may be altered in a variety of tissues in HD, including peripheral blood. Affymetrix and Amersham Biosciences oligonucleotide microarrays were used to analyze global gene expression in blood samp ...[more]

PMID: 16043692

Similar Datasets

Human blood expression for Huntington's disease versus control

Project description:Affymetrix U133A expression levels for 12 symptomatic and 5 presymptomatic Huntington's disease patients versus 14 healthy controls. Keywords: other

2005-09-13 | GSE1751 | GEO

Human blood expression for Huntington's disease versus control, Codelink

Project description:Codelink Human Uniset I, II, and 20K expression levels for 12 symptomatic and 5 presymptomatic Huntington's disease patients versus 14 healthy controls. Keywords: other

2005-07-22 | GSE1767 | GEO

2-year Longitudinal Analyses of Peripheral Blood RNA in Huntington's Disease gene-positive and control subjects

Project description:Samples collected in the course of the TRACK HD study and used to analyse association between gene expression in blood and symptomatic progression of Huntington's disease Longitudinal analysis of UHDRS TMS versus gene expression in individual subjects followed by cross-sectional comparisons across phenotype groups at each timepoint

2020-09-23 | GSE135589 | GEO

3′ sequencing from human Huntington's disease and control motor cortex and cerebellum.

Project description:Purpose: We applied polyA site sequencing (Passeq) to human Huntington's disease and control motor cortex and cerebellum to test if any genes change 3′UTR isoforms abundance. Methods: 3′ sequencing was performed on 6 motor cortices from grade 1 Huntington's patient brains, 4 motor cortices from grade 2 Huntington's patient brains, and 5 motor cortices from control brains. Cerebellum samples included 9 cerebella from grade 2-3 Huntington's patient brains, and 7 cerebella from control brains. To verify HTT isoforms in mice, sequencing was performed on 5 Q140 mouse striata and 3 wild-type mouse striata. Results: We report 11% of genes from Huntington's disease patient motor cortex exhibit a change in at least one of their 3′UTR isoforms, commensurate with the 11% of genes which show different total expression in HD motor cortex versus control. In contrast, gene isoform and expression changes are minimal (<5%) in Huntington's disease cerebellum versus controls. In the motor cortex, we show isoform and gene expression differs between between grade 1 and grade 2 brains. We identify a novel isoform of huntingtin mRNA which is conserved in wild-type and Huntington's model mice. Conclusions: This is the first study characterizing widespread alterations in 3′UTR isoform abundance in Huntington's disease. Alterations in isoform abundance may affect mRNA metabolism in Huntington's disease brains.

2017-09-21 | GSE96099 | GEO

Cell type specific gene expression analysis in pre-symptomatic huntington's disease.

Project description:Selective neuronal vulnerability is a common, yet poorly understood characteristic of neurodegenerative diseases and is particularly prominent in Huntington's disease (HD). To determine how presence of mutant prion protein influences gene expression at pre-symptomatic stages, we used RiboTag to isolate cell type-specific, translating RNA from GABAergic, glutamatergic, somatostatin- (SST) and parvalbumin-expressing neurons of 9-month-old knock-in mice of heterozygous for a Q185 expansion in the endogenous Hdh gene or littermate controls.

2022-11-04 | GSE199837 | GEO

Hdac4 interactome in Huntington's Disease

Project description:Hdac4 has been found to modulate symptoms in Huntington's Disease (HD) mouse models through an uknown mechanism unrelated to any enzymatic activity. We investigated the protein-protein interactions to gain insight into the role of Hdac4 in HD.

2019-05-01 | PXD011845 | Pride

Proteomic analysis of mitochondria from Huntington's Disease patient iPSC-derived neurons

Project description:Huntington's disease is caused by an expanded CAG repeat in the huntingtin gene, yeilding a Huntingtin protein with an expanded polyglutamine tract. Patient-derived induced pluripotent stem cells (iPSCs) can help understand disease; however, defining pathological biomarkers in challanging. Here we used LC-MS/MS to determine differences in mitochondrial proteome between iPSC-derived neurons from healthy donors and Huntington's disease patients.

2023-02-10 | PXD037526 | Pride

Cell type specific gene expression analysis in pre-symptomatic huntington's disease.

Project description:Cell type specific gene expression analysis in pre-symptomatic huntington's disease.

| PRJNA821671 | ENA

The transcriptional modulator H2AFY marks Huntington's disease activity in men and mice

Project description:To accelerate the development of disease-modifying therapeutics for Huntington’s disease (HD), a dynamic biomarker of disease activity and treatment response is critically needed. Venous cellular whole blood from 8 patients with Huntington's disease (HD) and 6 control subjects were collected in PAXgene tubes (Wiagen, Valencia, CA). RNA was isolated from whole blood using the PAXgene blood RNA kit (Qiagene) with DNase treatment. The biotinylated complementary RNA was fragmented and hybridized to Affymetrix human genome U133A microarrays. The Affymetrix .CEL files were normalized to “all probe sets” in a standardized matter, and scaled to 100 by the MAS5 5.0 algorithm implemented in the Bioconductor package.

2011-09-01 | E-GEOD-24250 | biostudies-arrayexpress

Genetic Modifiers of Huntington's Disease

Project description:Genetic Modifiers of Huntington's Disease

| PRJNA75833 | ENA